z-logo
open-access-imgOpen Access
The effectiveness of insulin glargine 300 U/mL among type 2 diabetes patients: Analysis of a real‐world data in Israel
Author(s) -
Melzer Cohen Cheli,
Ba Tamar,
Shalev Varda,
Chodick Gabriel
Publication year - 2020
Publication title -
endocrinology, diabetes and metabolism
Language(s) - English
Resource type - Journals
ISSN - 2398-9238
DOI - 10.1002/edm2.124
Subject(s) - medicine , insulin glargine , insulin , type 2 diabetes , diabetes mellitus , cohort , gastroenterology , hypoglycemia , endocrinology
Aims Randomized controlled trials have shown that insulin glargine 300 U/mL (Gla‐300) has a more stable and prolonged glucose lowering effect among patients with type 2 diabetes (T2DM) compared to insulin glargine 100 U/mL (Gla‐100), resulting in a reduced risk of hypoglycaemia while maintaining a similar efficacy of lowering HbA 1c . We aimed to investigate if the effectiveness of Gla‐300 is reproducible in real‐world settings. Material and methods In this retrospective cohort study, data from a large state‐mandated health organization were used to identify adult T2DM patients who were previously on insulin and initiated Gla‐300 therapy between 6/ 2016 and 12/2017. Changes in HbA 1c levels, body weight and insulin dose were calculated from baseline period and over a follow‐up period of 180 days. Documented hypoglycaemia events were also explored. Results A total of 1797 patients were included in this study with a mean age of 64.2 (SD = ±11.0y), baseline HbA 1c was 8.7 ± 1.6% and 42.5% were females. Among all patients with HbA 1c measurement during follow‐up (n = 1508), HbA 1c was significantly reduced by −0.6% (95% CI −0.6,−0.5; P  < .001) from baseline, with a significant reduction in body weight (−0.4 kg; P  = <.001). Additionally, a significant ( P  = .04) reduction of 40.5% in patients with hypoglycaemia events was recorded during follow‐up period, from 2.1% (n = 37) at the baseline period to 1.2% (n = 22). Conclusions This real‐world study supports evidence from RCTs regarding the effectiveness of Gla‐300 among T2DM patients by improving glycaemic control.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here